Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
about
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsIrritable bowel syndrome: new insights into symptom mechanisms and advances in treatmentThe potential utility of tight junction regulation in celiac disease: focus on larazotide acetateRecent Updates on the Treatment of ConstipationGuanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral painAdvances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideIrritable bowel syndrome: a concise review of current treatment conceptsLinaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adultsNovel therapies for constipationExperimental and computational evidence for an essential role of NaV1.6 in spike initiation at stretch-sensitive colorectal afferent endingsResponders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-CIrritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.Comparison of Hypnotherapy and Standard Medical Treatment Alone on Quality of Life in Patients with Irritable Bowel Syndrome: A Randomized Control Trial.Persistent constipation and abdominal adverse events with newer treatments for constipation.Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Placebo effect in clinical trial design for irritable bowel syndromeSildenafil normalizes bowel transit in preclinical models of constipationTenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationTranslating colorectal cancer prevention through the guanylyl cyclase C signaling axis.Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management.SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Recent advances in pharmacological treatment of irritable bowel syndrome.Irritable bowel syndrome: current and emerging treatment options.Irritable bowel syndrome: a clinical reviewImpact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trialsReview article: Linaclotide for the management of irritable bowel syndrome with constipationComparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C.Lubiprostone in constipation: clinical evidence and place in therapy.Optimal management of constipation associated with irritable bowel syndromeA comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosaLinaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialColonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation.
P2860
Q26748617-1AA621AD-A7DB-4F51-8509-14A5612C9BACQ26751193-17992B7B-C6A2-4E13-87E8-F75FA851A8E4Q26771888-18C7654D-329E-472E-A077-F696E830794DQ26820242-3A85FF75-CEB7-4002-93F1-7729CF06182AQ26863234-815A2CE4-E8B1-4DA1-81E1-9195B65A0D71Q26865304-8040D9CE-CDCB-453E-B67A-08C616904E55Q26996547-A1D49C17-52F4-4EA5-BD71-C9B9EA8FAC1EQ27010449-92F0D103-08D6-4EF1-8DBC-8530923ECC9CQ27027873-9424239C-8E9C-4235-8FC3-E54E7F15678DQ30646640-AC5BB392-133E-42E8-B766-A8913A477B97Q30724990-06519EA4-3BEC-47AB-862C-D884657B950AQ33463901-45531ACE-F05A-46B2-B87E-934524E47260Q33468462-4DDADDAB-3BE9-45F0-B589-A318460D652CQ33468562-5EE1CACB-1807-49C1-9D9B-C2572EFB5FB7Q33586854-B904EA4C-77AF-4DFA-8FBB-95A5B61B3D7EQ33586880-461CFC56-A84D-4A81-B082-93FB536B918FQ33610799-93DB0B32-5EA6-41C8-91F9-3279503304DAQ33639963-6B70290B-C254-4765-A0CE-939A030A1B6BQ33695487-3119EE0C-5CCF-4F93-B299-DE88C40715E0Q33722761-14CB95F9-0C0E-4405-B974-0B9FEE84C7B1Q33855973-4ABAF8A0-B912-4A3D-A86E-519A0786540EQ33865075-14EE625D-10A0-4371-B28B-FF20EFAA95C3Q33958710-521004FB-1981-473B-90F3-4798EABC4C67Q33958853-80148EE8-357E-4A0F-A538-66D340EDB4DEQ34010550-3B45688D-F1B5-4F78-A971-1864B24CAE92Q34168517-EC348667-279B-49A3-A662-577989AEB5D2Q34179472-A5B51715-793E-44EB-80AE-FD5C961A7868Q34309302-22F567CF-5633-41BE-B2D8-4FF5FF39A13AQ34392861-E62B06FB-51D2-4F70-881D-37258414C313Q34478089-8C15FDB3-C5F2-4948-BF7A-065D4B857194Q34577699-CAE86759-4279-463E-979E-4BECE78FBB7CQ34645550-51D1DF3D-3F1A-42C5-8E44-BC8F156DCBCFQ34782198-00343C91-C3AE-4F59-A030-69A81053A7BAQ35008626-95DFDD38-6816-40E9-8178-952DBF97695DQ35044200-20C2D5B8-A064-45AC-98B4-6B38260A4BC2Q35091370-602AA39B-20B0-48AA-BE51-478CEB08B19CQ35586543-C8620901-D64F-4685-B9C4-6C838EE71BDCQ35664952-AAA7BCFC-647D-402A-87CE-8213D6ECE6F0Q35723125-B601E648-62B9-40E1-9AC7-4E21B60774C6Q35922325-62EED6F0-8076-4881-8F75-F035AE728246
P2860
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@en
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@nl
type
label
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@en
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@nl
prefLabel
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@en
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@nl
P2093
P2860
P921
P356
P1476
Linaclotide for irritable bowe ...... evaluate efficacy and safety.
@en
P2093
Anthony J Lembo
Bernard J Lavins
Caroline B Kurtz
Donald A Fitch
Harvey A Schneier
James E MacDougall
James Z Shao
Jeffrey M Johnston
Mark G Currie
Mollie J Baird
P2860
P304
P356
10.1038/AJG.2012.254
P407
P577
2012-11-01T00:00:00Z